AnaptysBio (ANAB) Projected to Post Earnings on Monday

AnaptysBio (NASDAQ:ANAB) is anticipated to announce its earnings results before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of ($1.55) per share and revenue of $7.79 million for the quarter.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.61) by $0.89. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The company had revenue of $43.11 million during the quarter, compared to analyst estimates of $10.17 million. On average, analysts expect AnaptysBio to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

AnaptysBio Stock Performance

Shares of NASDAQ:ANAB opened at $16.34 on Friday. AnaptysBio has a 52-week low of $12.21 and a 52-week high of $41.31. The firm has a fifty day moving average of $16.23 and a 200 day moving average of $23.99. The firm has a market capitalization of $501.10 million, a PE ratio of -2.69 and a beta of 0.02.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Wells Fargo & Company upped their target price on shares of AnaptysBio from $40.00 to $51.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. BTIG Research lowered shares of AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. HC Wainwright reiterated a “neutral” rating and issued a $22.00 target price on shares of AnaptysBio in a research report on Tuesday, March 4th. Truist Financial cut their target price on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research report on Wednesday, December 18th. Finally, Wedbush restated an “outperform” rating and set a $40.00 price target on shares of AnaptysBio in a research report on Wednesday, February 12th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.11.

Insider Buying and Selling at AnaptysBio

In other news, Director Ecor1 Capital, Llc acquired 6,646 shares of the stock in a transaction dated Thursday, January 2nd. The stock was purchased at an average cost of $12.95 per share, with a total value of $86,065.70. Following the completion of the purchase, the director now owns 7,880,094 shares in the company, valued at approximately $102,047,217.30. The trade was a 0.08 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 33.70% of the company’s stock.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.